FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
2.240
-0.140 (-5.88%)
At close: Nov 20, 2024, 4:00 PM
2.290
+0.050 (2.23%)
After-hours: Nov 20, 2024, 7:57 PM EST
FibroBiologics Employees
FibroBiologics had 10 employees as of December 31, 2023. The number of employees increased by 3 or 42.86% compared to the previous year.
Employees
10
Change (1Y)
3
Growth (1Y)
42.86%
Revenue / Employee
n/a
Profits / Employee
-$1,777,900
Market Cap
77.64M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10 | 3 | 42.86% |
Dec 31, 2022 | 7 | - | - |
Related Stocks
Company Name | Employees |
---|---|
EDAP TMS | 307 |
WORK Medical Technology Group LTD | 216 |
Veru Inc. | 189 |
CASI Pharmaceuticals | 176 |
HilleVax | 90 |
MediciNova | 13 |
Regencell Bioscience Holdings | 12 |
CervoMed | 8 |
FBLG News
- 1 day ago - FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly - GlobeNewsWire
- 6 days ago - FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics - GlobeNewsWire
- 8 days ago - FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 23 days ago - FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology - GlobeNewsWire
- 24 days ago - FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024 - GlobeNewsWire
- 4 weeks ago - FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases - GlobeNewsWire
- 5 weeks ago - FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office - GlobeNewsWire
- 5 weeks ago - FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire